Business
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
- Presentations to cover clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program, including lead candidate VRDN-001 -
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"\n- Presentations to cover clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program, including lead candidate VRDN-001 -\n\n\n WALTHAM, Mass.--(BUSINESS WIRE)--\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the following medical meetings:\n\n\n\nThe 45th Annual Meeting of the European Thyroid Association (ETA) to be held September 9-12, 2023, in Milan, Italy\n\n\n\nThe 41st Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) to be held September 14-16, 2023, in Naples, Italy\n\n\n\nThe Annual Meeting of the American Thyroid Association (ATA) to be held September 27-October 1, 2023, in Washington, DC\n\n\n\nPresentations at all three conferences will highlight clinical and pharmacologic data from studies of VRDN-001, a full antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R), in development for TED. An additional presentation will feature pharmacokinetic data for VRDN-003, a next-generation, half-life extended antibody to IGF-1R for TED. The Company will also present clinical pharmacodynamic responses to VRDN-001 in healthy volunteers and patients with active TED.\n\n\n\nConference: ETA\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTitle:\n\n\n\n\n\n\n\nVRDN-001, a Full Antagonist Antibody to IGF-1 Receptor: In Vitro Pharmacology and Phase 1/2 Results in Patients with Thyroid Eye Disease\n\n\n\n\n\n\n\n\nSession:\n\n\n\n\n\n\n\nOral Session 9—Thyroid Eye Disease\n\n\n\n\n\n\n\n\nInformation:\n\n\n\n\n\n\n\nMonday, September 11, 2023, 2:40 to 2:52 pm CET\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTitle:\n\n\n\n\n\n\n\nPreclinical Pharmacokinetics and Clinical Exposure Prediction for VRDN-003, a Next-Generation Half-life Extended Antibody to IGF-1R for Thyroid Eye Disease\n\n\n\n\n\n\n\n\nSession:\n\n\n\n\n\n\n\nOral Session 9—Thyroid Eye Disease\n\n\n\n\n\n\n\n\nInformation:\n\n\n\n\n\n\n\nMonday, September 11, 2023, 2:52 to 3:04 pm CET\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nConference: ESOPRS\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTitle:\n\n\n\n\n...